One-year outcomes of intravitreal bevacizumab (avastin) therapy for polypoidal choroidal vasculopathy.
Retina
; 31(5): 846-56, 2011 May.
Article
em En
| MEDLINE
| ID: mdl-21317837
ABSTRACT
PURPOSE:
To report on 1-year visual, anatomical, and angiographic responses with intravitreal bevacizumab for the treatment of polypoidal choroidal vasculopathy.METHODS:
Patients with macula-involved, symptomatic polypoidal choroidal vasculopathy with initial best-corrected visual acuity of 20/400 or better and a minimal follow-up period of 12 months were retrospectively enrolled. Eyes were treated with intravitreal bevacizumab (2.5 mg) at baseline and monitored monthly for best-corrected visual acuity and central retinal thickness (by optical coherence tomography). Indocyanine green angiography was evaluated on a 6-month basis. Eyes were retreated on an "as-needed" basis according to visual and anatomical changes.RESULTS:
A total of 35 eyes of 33 patients were treated with a mean of 3.3 (range, 1-8) times of injection. Best-corrected visual acuity significantly improved from a mean logarithm of the minimum angle of resolution of 0.79 ± 0.42 at baseline (Snellen equivalent, 20/123) to 0.69 ± 0.47 (20/94), 0.66 ± 0.45 (20/87), 0.67 ± 0.44 (20/87), 0.67 ± 0.48 (20/87), and 0.67 ± 0.51 (20/87) at 1, 3, 6, 9, and 12 months, respectively (P = 0.002, 0.0003, 0.0008, 0.017, and 0.02, respectively; paired Student's t-test). Central retinal thickness also significantly improved from a mean of 297 ± 94 µm at baseline to 215 ± 58 µm, 214 ± 59 µm, 218 ± 79 µm, 213 ± 75 µm, and 221 ± 61 µm at 1, 3, 6, 9, and 12 months, respectively (all P < 0.0001, paired Student's t-test). Indocyanine green angiography showed 3 of 32 eyes (9.4%) and 5 of 31 eyes (16.1%) with completely resolved polyps and 11 of 32 eyes (34.4%) and 10 of 31 eyes (32.3%) with reduced polyps at 6 and 12 months, respectively. No systemic complication or severe local complication, such as endophthalmitis, was found.CONCLUSION:
Intravitreal bevacizumab therapy has a favorable outcome in improving visual acuity and macular exudative changes in patients with polypoidal choroidal vasculopathy. It can also moderately reduce polypoidal lesions on indocyanine green angiography.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Doenças da Coroide
/
Corioide
/
Doenças Vasculares Periféricas
/
Inibidores da Angiogênese
/
Anticorpos Monoclonais Humanizados
Tipo de estudo:
Diagnostic_studies
/
Observational_studies
/
Prognostic_studies
Limite:
Aged
/
Aged80
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Ano de publicação:
2011
Tipo de documento:
Article